Diagnostik und Therapie choroidaler Melanome

Zusammenfassung

Hintergrund: In der Diagnostik der Aderhaut- und Ziliarkörpermelanome gibt es wesentliche Fortschritte in der Bestimmung der Prognose durch Untersuchung zytogenetischer Tumoreigenschaften. Auch die neue TNM-Klassifikation dient der Einschätzung der Überlebenswahrscheinlichkeit in Abhängigkeit der klinisch bestimmbaren Tumorgröße und -ausdehnung.

Material und Methoden: Darstellung der aktuellen diagnostischen und therapeutischen Möglichkeiten des Aderhautmelanoms.

Ergebnisse: Während im Ergebnis der lokalen Strahlentherapie mittels Brachy-, Protonen- und Photonentherapie sowie der Tumorchirurgie meistens eine Organerhaltung möglich ist, bleibt die Überlebenswahrscheinlichkeit im Vergleich zur primären Enukleation aufgrund einer hämatogenen Mikrometastasierung vor Therapiebeginn unverändert.

Schlussfolgerung: Die Prognose der häufigsten intraokularen Tumoren kann gegenwärtig lediglich durch eine frühzeitigere augenärztliche Identifikation und Behandlung verbessert werden.

Abstract

Background: Prognosis evaluation of patients with choroidal and ciliary melanoma has experienced recent progress through tumour sampling and cytogenetic analysis of metastatic risk. By allocating tumor extension, height and linear basal diameter to defined TNM stages, an estimation of prognosis can also be made without invasive tissue sampling.

Methods: Therapeutic strategies of organ preserving irradiation using different sources have clearly come to the forefront.

Results: Due to microscopic haematogenous spreading of tumour cells prior to treatment, the metastatic risk following radiation of any form is not influenced in comparison to primary enucleation.

Conclusion: However, metastatic disease still remains a fatal condition which currently may only be influenced by early detection and treatment of uveal melanomas.

Schlüsselwörter

malignes Melanom der Aderhaut - Aderhautmelanom (AHMM) - Ziliarkörpermelanom (ZKMM) - uveales Melanom

Key words

malignant uveal melanoma - choroidal melanoma - ciliary body melanoma - uveal melanoma

• Literatur

• 1 Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011; 118: 1881-1885
• 2 Prescher G, Bornfeld N, Becher R. Nonrandom chromosomal abnormalities in primary uveal melanoma. J Natl Cancer Inst 1990; 82: 1765-1769
• 3 Horsthemke B, Prescher G, Bornfeld N et al. Loss of chromosome 3 alleles and multiplication of chromosome 8 alleles in uveal melanoma. Genes Chromosomes Cancer 1992; 4: 217-221
• 4 Prescher G, Bornfeld N, Hirche H et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347: 1222-1225
• 5 Damato B, Eleuteri A, Taktak A et al. Estimating prognosis for survival after treatment of choroidal melanoma. Prog Retin Eye Res 2011; 30: 285e295
• 6 Wagoner MD, Albert DM. The incidence of metastases from untreated ciliary body and choroidal melanoma. Arch Ophthalmol 1982; 100: 939-940
• 7 Dithmar S, Diaz CE, Grossniklaus HE. Intraocular melanoma spread to regional lymph nodes: report of two cases. Retina 2000; 20: 76-79
• 8 Tojo D, Wenig BL, Resnick KI. Incidence of cervical metastasis from uveal melanoma: implications for treatment. Head Neck 1995; 17: 137-139
• 9 Heindl LM, Hofmann TN, Knorr HL et al. Intraocular lymphangiogenesis in malignant melanomas of the ciliary body with extraocular extension. Invest Ophthalmol Vis Sci 2009; 50: 1988-1995
• 10 Khan AM, Kagan DB, Gupta N et al. Ciliary body lymphangiogenesis in uveal melanoma with and without extraocular extension. Ophthalmology 2013; 120: 306-310
• 11 Shah CP, Weis E, Lajous M et al. Intermittent and chronic ultraviolet light exposure and uveal melanoma: a meta-analysis. Ophthalmology 2005; 112: 1599-1607
• 12 Stang A, Anastassiou G, Ahrens W et al. The possible role of radiofrequency radiation in the development of uveal melanoma. Epidemiology 2001; 12: 7-12
• 13 Virgili G, Gatta G, Ciccolallo L et al. Incidence of uveal melanoma in Europe. Ophthalmology 2007; 114: 2309-2315
• 14 Hu DN, McCormick SA, Yu GP. Latitude and uveal melanoma. Ophthalmology 2008; 115: 757 (author reply 757–759)
• 15 Coupland SE, Lake SL, Zeschnigk M et al. Molecular pathology of uveal melanoma. Eye 2013; 27: 230-242
• 16 Sisley K, Doherty R, Cross NA. What hope for the future? GNAQ and uveal melanoma. Br J Ophthalmol 2011; 95: 620-623
• 17 Eskelin S, Pyrhönen S, Summanen P et al. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology 2000; 107: 1443-1449
• 18 Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44: 4651-4659
• 19 Diener-West M, Earle JD, Fine SL et al. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001; 119: 969-982
• 20 Bove R, Char DH. Nondiagnosed uveal melanomas. Ophthalmology 2004; 111: 554-557
• 21 Damato B. Detection of uveal melanoma by optometrists in the United Kingdom. Ophthalmic Physiol Opt 2001; 21: 268-271
• 22 Eskelin S, Kivelä T. Mode of presentation and time to treatment of uveal melanoma in Finland. Br J Ophthalmol 2002; 86: 333-338
• 23 Ah-Fat FG, Damato BE. Delays in the diagnosis of uveal melanoma and effect on treatment. Eye 1998; 12: 781-782
• 24 Singh AD. Uveal melanoma: implications of tumor doubling time. Ophthalmology 2001; 108: 829-831
• 25 Shields CL, Furuta M, Berman EL et al. Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases. Arch Ophthalmol 2009; 127: 981-987
• 26 Damato BE. Tumour fluorescence and tumour-associated fluorescence of choroidal melanomas. Eye 1992; 6: 587-593
• 27 Shields CL, Pirondini C, Bianciotto C et al. Autofluorescence of choroidal nevus in 64 cases. Retina 2008; 28: 1035-1043
• 28 Kivelä T. Diagnosis of uveal melanoma. Dev Ophthalmol 2012; 49: 1-15
• 29 Akgül H, Otterbach F, Bornfeld N et al. Intraocular biopsy using special forceps: a new instrument and refined surgical technique. Br J Ophthalmol 2011; 95: 79-82
• 30 Augsburger JJ, Shields JA. Fine needle aspiration biopsy of solid intraocular tumors: indications, instrumentation and techniques. Ophthalmic Surg 1984; 15: 34-40
• 31 Damato B. Does ocular treatment of uveal melanoma influence survival?. Br J Cancer 2010; 1033: 285-290
• 32 Sumich P, Mitchell P, Wang JJ. Choroidal nevi in a white population: the Blue Mountains Study. Arch Ophthalmol 1998; 116: 645-650
• 33 Shields CL, Cater JC, Shields JA et al. Combination of clinical factors predictive of growth of small choroidal melanocytic tumors. Arch Ophthalmol 2000; 18: 360-364
• 34 Finger PT. Do you speak ocular tumor?. Ophthalmology 2003; 110: 13-14
• 35 Diener-West M, Hawkins BS, Markowitz JA et al. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 1992; 110: 245-250
• 36 Kivelä T, Kujala E. Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond. Eye 2013; 27: 243-252
• 37 Speicher MR, Prescher G, du Manoir S et al. Chromosomal gains and losses in uveal melanomas detected by comparative genomic hybridization. Cancer Res 1994; 54: 3817-3823
• 38 Onken MD, Worley LA, Ehlers JP et al. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004; 64: 7205-7209
• 39 Lommatzsch P. Treatment of choroidal melanomas with 106Ru/106Rh beta-ray applicators. Surv Ophthalmol 1974; 19: 85-100
• 40 Packer S, Rotman M. Radiotherapy of choroidal melanoma with iodine 125. Int Ophthalmol Clin 1980; 20: 135-142
• 41 Finger PT. Radiation therapy for choroidal melanoma. Surv Ophthalmol 1997; 42: 215-232
• 42 Astrahan M, Luxton G, Jozsef G et al. An interactive treatment planning system for ophthalmic plaque radiotherapy. Int J Radiat Oncol Biol Phys 1990; 18: 679-687
• 43 Hawkins BS. Collaborative ocular melanoma study randomized trial of I-125 brachytherapy. Clin Trials 2011; 8: 661-673
• 44 Sagoo MS, Shields CL, Mashayekhi A et al. Plaque radiotherapy for juxtapapillary choroidal melanoma: tumor control in 650 consecutive cases. Ophthalmology 2011; 118: 402-407
• 45 Bornfeld N. Proton treatment of uveal melanomas. Strahlenther Onkol 2007; 183: 1-2
• 46 Höcht S, Bechrakis NE, Nausner M et al. Proton therapy of uveal melanomas in Berlin. 5 years of experience at the Hahn-Meitner Institute. Strahlenther Onkol 2004; 180: 419-424
• 47 Dunavoelgyi R, Dieckmann K, Gleiss A et al. Radiogenic side effects after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007. Int J Radiat Oncol Biol Phys 2012; 83: 121-128
• 48 Dunavoelgyi R, Dieckmann K, Gleiss A et al. Local tumor control, visual acuity, and survival after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007. Int J Radiat Oncol Biol Phys 2011; 81: 199-205
• 49 Zehetmayer M. Stereotactic photon beam irradiation of uveal melanoma. Dev Ophthalmol 2012; 49: 58-65
• 50 Egan KM, Ryan LM, Gragoudas ES. Survival implications of enucleation after definitive radiotherapy for chroidal melanoma: an example of regression on the time-dependent covariantes. Arch Ophthalmol 1998; 116: 336-370
• 51 Jampol LM, Moy CS, Murray TG et al. Collaborative Ocular Melanoma Study Group (COMS Group). The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology 2002; 109: 2197-2206
• 52 Verschueren KM, Creutzberg CL, Schalij-Delfos NE et al. Long-term outcomes of eye-conserving treatment with Ruthenium(106) brachytherapy for choroidal melanoma. Radiother Oncol 2010; 95: 332-338
• 53 Rouberol F, Roy P, Kodjikian L et al. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 yearsʼ experience with beta-rays). Am J Ophthalmol 2004; 137: 893-900
• 54 Wilson MW, Hungerford JL. Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. Ophthalmology 1999; 106: 1579-1587
• 55 Damato B, Patel I, Campbell IR et al. Local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys 2005; 63: 385-391
• 56 Shields CL, Shields JA, Perez N et al. Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations. Ophthalmology 2002; 109: 225-234
• 57 Singh AD, Eagle jr. RC, Shields CL et al. Clinopathologic reports, case reports, and small case series: enucleation following transpupillary thermotherapy of chroidal melanoma: clinicopathological correlations. Arch Ophthalmol 2003; 121: 397-400
• 58 Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C et al. Treatment of uveal melanoma by accelerated proton beam. Dev Ophthalmol 2012; 49: 41-57
• 59 Damato B, Groenewald C, McGalliard J et al. Endoresection of choroidal melanoma. Br J Ophthalmol 1998; 82: 213-218
• 60 Parrozzani R, Pilotto E, Dario A. Intravitreal triamcinolone versus intravitreal bevacizumab in the treatment of exudative retinal detachment secondary to posterior uveal melanoma. Am J Ophthalmol 2013; 155: 127-133
• 61 Gündüz K, Shields CL, Shields JA et al. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol 1999; 117: 609-614
• 62 Finger PT. Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol 2000; 84: 1068-1070
• 63 Kinyoun JL. Long-term visual acuity results of treated and untreated radiation retinopathy. Trans Am Ophthalmol Soc 2008; 106: 325-335
• 64 Kinyoun JL, Lawrence BS, Barlow WE. Proliferative radiation retinopathy. Arch Ophthalmol 1996; 114: 1097-1100
• 65 Missotten GS, Keunen JE. Screening for uveal melanoma metastasis. Literature review. Bull Soc Belge Ophtalmol 2004; 294: 13-22
• 66 Lorigan JG, Wallace S, Mavligit GM. The prevalence and location of metasteses from ocular melanoma: imaging study in 110 patients. Am J Roentgenol 1991; 157: 1279-1281
• 67 Kaiserman I, Amer R, Peʼer J. Liver function tests in metastatic uveal melanoma. Am J Ophthalmol 2004; 137: 236-243
• 68 Diener-West M, Reynolds SM, Agugliaro DJ et al. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol 2004; 22: 2438-2444
• 69 Barak V, Kaiserman I, Frenkel S et al. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1). Anticancer Res 2011; 31: 345-349
• 70 Willerding G, Heufelder J, Kakkassery V, Cordini D, Joussen AM. Strahlenretinopathie. In: Joussen A, Hrsg. Retinale Gefäßerkrankungen. Berlin, Heidelberg: Springer; 2012: 306-319
• 71 Leyvraz S, Keilholz U. Ocular melanoma: whatʼs new?. Curr Opin Oncol 2012; 24: 162-169
• 72 Schmittel A, Schmidt-Hieber M, Martus P et al. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol 2006; 17: 1826-1829
• 73 Schuster R, Lindner M, Wacker F et al. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome. Melanoma Res 2010; 20: 191-196